JURNISTA hydromorphone hydrochloride 4 mg prolonged release tablet blister pack Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

jurnista hydromorphone hydrochloride 4 mg prolonged release tablet blister pack

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 4 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; hypromellose; macrogol 3350; iron oxide yellow; lactose; titanium dioxide; macrogol 400; iron oxide red; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.

JURNISTA hydromorphone hydrochloride 64 mg prolonged release tablet blister pack Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

jurnista hydromorphone hydrochloride 64 mg prolonged release tablet blister pack

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 64 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; hypromellose; lactose; macrogol 3350; lactose monohydrate; titanium dioxide; triacetin; indigo carmine aluminium lake; macrogol 400; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.

JURNISTA hydromorphone hydrochloride 32 mg prolonged release tablet blister pack Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

jurnista hydromorphone hydrochloride 32 mg prolonged release tablet blister pack

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 32 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; iron oxide yellow; hypromellose; lactose; macrogol 3350; lactose monohydrate; titanium dioxide; triacetin; macrogol 400; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.

JURNISTA hydromorphone hydrochloride 16 mg prolonged release tablet blister pack Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

jurnista hydromorphone hydrochloride 16 mg prolonged release tablet blister pack

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 16 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; hypromellose; lactose; macrogol 3350; lactose monohydrate; titanium dioxide; triacetin; iron oxide yellow; macrogol 400; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.

JURNISTA hydromorphone hydrochloride 8 mg prolonged release tablet blister pack Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

jurnista hydromorphone hydrochloride 8 mg prolonged release tablet blister pack

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 8 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; hypromellose; lactose; macrogol 3350; lactose monohydrate; titanium dioxide; triacetin; iron oxide red; macrogol 400; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.

Armoneve 2.5 mg/1.25 mg prolonged-release tablets Irlanda - anglès - HPRA (Health Products Regulatory Authority)

armoneve 2.5 mg/1.25 mg prolonged-release tablets

mundipharma pharmaceuticals limited - oxycodone hydrochloride; naloxone hydrochloride dihydrate - prolonged-release tablet - 2.5/1.25 mg/mg - natural opium alkaloids; oxycodone, combinations

Armoneve 30 mg/15 mg prolonged-release tablets Irlanda - anglès - HPRA (Health Products Regulatory Authority)

armoneve 30 mg/15 mg prolonged-release tablets

mundipharma pharmaceuticals limited - oxycodone hydrochloride; naloxone hydrochloride dihydrate - prolonged-release tablet - 30/15 mg/mg - natural opium alkaloids; oxycodone, combinations

Armoneve 15 mg/7.5 mg prolonged-release tablets Irlanda - anglès - HPRA (Health Products Regulatory Authority)

armoneve 15 mg/7.5 mg prolonged-release tablets

mundipharma pharmaceuticals limited - oxycodone hydrochloride; naloxone hydrochloride dihydrate - prolonged-release tablet - 15/7.5 mg/mg - natural opium alkaloids; oxycodone, combinations

Dancex SR 5 mg Prolonged-Release Tablets Irlanda - anglès - HPRA (Health Products Regulatory Authority)

dancex sr 5 mg prolonged-release tablets

rowex ltd - oxycodone hydrochloride - prolonged-release tablet - 5 milligram(s) - natural opium alkaloids; oxycodone

Dancex SR 10 mg Prolonged-Release Tablets Irlanda - anglès - HPRA (Health Products Regulatory Authority)

dancex sr 10 mg prolonged-release tablets

rowex ltd - oxycodone hydrochloride - prolonged-release tablet - 10 milligram(s) - natural opium alkaloids; oxycodone